Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Degree

Medical Specialty

Submit

Key HIV Studies Influencing My Practice Following CROI 2022—Dr. Daniel Kuritzkes and Dr. David Wohl

Source: Conference Coverage of CROI 2022: Clinical Impact of New HIV Data*

February 13-16, 2022; Virtual

Hear from CCO’s expert faculty members as they present their insights on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Daniel R. Kuritzkes, MD

David A. Wohl, MD

Released: March 3, 2022

Information on this Educational Activity

Faculty

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has reported that he has received funds for research support from Gilead Sciences, Merck, and ViiV Healthcare and consultant/advisor/speaker fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV Healthcare, and ViroStatics.

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases
Clinical Trials Unit
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

David A. Wohl, MD, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV.